Comparing two ways to start etoposide for severe HLH in ICU
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial compares two ways to start etoposide, a chemotherapy drug, for people with severe HLH who are in the ICU and have organ failure. It aims to see which approach improves survival and recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have been diagnosed with HLH for the first time.
- You are in the intensive care unit (ICU).
- You have at least one organ failing (heart, lungs, kidneys, or brain).
- You can start etoposide within 12 hours and have not already received it for this HLH episode.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of surgery (segmental resection of the damaged intestine) plus a chemotherapy regimen called DEP (doxorubicin, etoposide, and methylprednisolone) for people with HLH caused by Epstein-Barr virus that has severely affected the intestines. It aims to improve outcomes by removing the infected tissue and targeting the virus.
This trial tests a combination of a targeted drug (ruxolitinib) with a less intense version of standard chemo for adults with Hemophagocytic Lymphohistiocytosis (HLH). It aims to control the overactive immune response while reducing side effects.
This trial studies whether giving high-dose cyclophosphamide as an initial treatment works better for adults with HLH. HLH is a serious, overactive immune condition, and the study aims to improve control of the illness and safety.
This trial compares two ways to collect your own stem cells before a transplant in people with non-Hodgkin's lymphoma who are in remission. The goal is to see which method works better for getting enough healthy cells.
This trial tests a combination of five drugs to treat a rare blood cancer called NK/T-cell lymphoma that has triggered an abnormal immune response (hemophagocytic lymphohistiocytosis). The goal is to control both the cancer and the harmful immune reaction.
This trial tests a modified combination of drugs (liposomal doxorubicin, etoposide, and ruxolitinib, with or without a PD-1 inhibitor) for people with HLH. The goal is to see if it helps control the overactive immune response better than standard care.
Hear when a new Hemophagocytic Lymphohistiocytosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.